{"protocolSection": {"identificationModule": {"nctId": "NCT04673630", "orgStudyIdInfo": {"id": "D5180C00025"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma", "officialTitle": "A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children \u2265 5 to 11 Years of Age With Mild, Moderate, or Severe Asthma (TRAILHEAD)", "acronym": "TRAILHEAD"}, "statusModule": {"statusVerifiedDate": "2023-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-02-23", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-09-27", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-09-27", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-12-02", "studyFirstSubmitQcDate": "2020-12-16", "studyFirstPostDateStruct": {"date": "2020-12-17", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-03-29", "resultsFirstSubmitQcDate": "2023-03-29", "resultsFirstPostDateStruct": {"date": "2024-01-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-03-29", "lastUpdatePostDateStruct": {"date": "2024-01-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Amgen", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged \u2265 5 to 11 years with asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Mild asthma", "Moderate asthma", "Severe asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE", "maskingDescription": "No masking is used. All involved know the identity of the intervention assignment."}}, "enrollmentInfo": {"count": 18, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tezepelumab", "type": "EXPERIMENTAL", "description": "Tezepelumab subcutaneous injection", "interventionNames": ["Biological: Tezepelumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Tezepelumab", "description": "Single dose subcutaneous injection", "armGroupLabels": ["Tezepelumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximum Observed Serum Concentration (Cmax) of Tezepelumab", "description": "Blood samples were collected to determine the Cmax of tezepelumab. The Pharmacokinetic (PK) parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}, {"measure": "Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab", "description": "Blood samples were collected to determine the tmax of tezepelumab. The PK parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}, {"measure": "Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab", "description": "Blood samples were collected to determine the AUC0-last of tezepelumab and calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}, {"measure": "Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab", "description": "Blood samples were collected to determine the AUC0-inf of tezepelumab and calculated by linear up/log down trapezoidal summation and extrapolated to infinity by the addition of the last quantifiable concentration divided by the terminal rate constant. The PK parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}, {"measure": "Terminal Phase Elimination Half-Life (t1/2) of Tezepelumab", "description": "Blood samples were collected to determine the t1/2 of tezepelumab and calculated as ln(2)/\u03bbZ, where \u03bbZ is the first-order rate constant associated with the terminal (log-linear) elimination phase. The PK parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}, {"measure": "Apparent Clearance (CL/F) of Tezepelumab", "description": "Blood samples were collected to determine the CL/F of tezepelumab and estimated as dose divided by AUC0-inf. The PK parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}, {"measure": "Apparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab", "description": "Blood samples were collected to determine the Vss/F of tezepelumab and estimated as CL/F\\*mean residence time (MRT), where MRT=Area under the moment curve of the analyte in the sampled matrix from zero (predose) extrapolated to infinite time/(AUC0-inf). The PK parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}, {"measure": "Apparent Volume of Distribution (Vz/F) of Tezepelumab", "description": "Blood samples were collected to determine the Vz/F of tezepelumab and estimated as CL/F\\*1/ \u03bbZ. The PK parameters were estimated using non-compartmental analysis method.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85"}], "secondaryOutcomes": [{"measure": "Number of Participants With Anti-Drug Antibody (ADA) Response to Tezepelumab", "description": "Blood samples were analyzed for the presence of ADAs for tezepelumab using validated assays. ADA prevalence was defined as ADA positive at baseline and/or post baseline. ADA incidence was defined as the percentage of treatment-emergent ADA positive participants in a population. Treatment induced ADA positive was defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive was defined as baseline positive ADA titre that was boosted to a 4-fold or higher level following study drug administration. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive.", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 29 and 85"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent and written informed assent and any locally required authorisation obtained from the subject and legal representative prior to any study related procedure taking place.\n* Age 5 to 11 years (inclusive) at Visit 1 and Visit 2 (Day 1). Type of Subject and Disease Characteristics\n* Documented physician diagnosed asthma for at least 6 months prior to Visit 1.\n* Documented treatment with total daily dose of either low, medium, or high dose ICS for at least 6 months, as described in Step 2 to Step 4 of GINA guidelines (GINA 2020) with stable dose for at least 3 months prior to Visit 1.\n* Pre bronchodilator (BD) FEV1 of \u2265 50% of predicted normal value at Visit 1\n* Body weight \u2265 16 kg at Visit 1 and Visit 2 (Day 1).\n\nExclusion Criteria:\n\n* History of any clinically significant disease or disorder other than asthma which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.\n* History of a deterioration in asthma or asthma exacerbation that required a burst of systemic corticosteroids within 6 weeks of Visit 1, up to and including Visit 2 (Day 1).\n* History of hospitalisation (overnight admission) for asthma within 3 months of Visit 1, up to and including Visit 2 (Day 1).\n* History of a life threatening asthma exacerbation requiring intubation or mechanical ventilation.\n* History of systemic corticosteroid use for the maintenance treatment of asthma within 6 weeks of Visit 1, up to and including Visit 2 (Day 1) and discouraged until EOS.\n* History of cancer.\n* History of hypersensitivity or anaphylactic reaction to any biologic therapy.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "5 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jonathan Grigg, MD", "affiliation": "Royal London Hospital, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Budapest", "zip": "1094", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Bristol", "zip": "BS2 8BJ", "country": "United Kingdom", "geoPoint": {"lat": 51.45523, "lon": -2.59665}}, {"facility": "Research Site", "city": "Glasgow", "zip": "G51 4TF", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Research Site", "city": "London", "zip": "E1 1BB", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Research Site", "city": "London", "zip": "SE5 9RS", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "CSR Synopsis", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00025&amp;attachmentIdentifier=4e88e9dc-f504-4df4-ab92-5048a89f274c&amp;fileName=D5180C00025_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.", "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study consists a screening period (14 days), and a single dose treatment (Day 1) and follow-up period (85 days). A total of 18 participants were treated in the study.", "recruitmentDetails": "This Phase I open-label study was conducted in pediatric participants with mild, moderate, or severe asthma at 6 investigational sites in the UK, Hungary, and South Africa between 23 February 2021 and 27 September 2022.", "groups": [{"id": "FG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab subcutaneous (SC) injection on Day 1."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The Safety analysis set included all participants who received at least 1 dose of tezepelumab.", "groups": [{"id": "BG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.9", "spread": "1.78"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "9"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "18"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximum Observed Serum Concentration (Cmax) of Tezepelumab", "description": "Blood samples were collected to determine the Cmax of tezepelumab. The Pharmacokinetic (PK) parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "microgram per milliliter (mcg/mL)", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.1", "spread": "11.9"}]}]}]}, {"type": "PRIMARY", "title": "Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab", "description": "Blood samples were collected to determine the tmax of tezepelumab. The PK parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "day", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.47", "lowerLimit": "1.92", "upperLimit": "9.96"}]}]}]}, {"type": "PRIMARY", "title": "Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab", "description": "Blood samples were collected to determine the AUC0-last of tezepelumab and calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "day*mcg/mL", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "872", "spread": "285"}]}]}]}, {"type": "PRIMARY", "title": "Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab", "description": "Blood samples were collected to determine the AUC0-inf of tezepelumab and calculated by linear up/log down trapezoidal summation and extrapolated to infinity by the addition of the last quantifiable concentration divided by the terminal rate constant. The PK parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "day*mcg/mL", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "974", "spread": "320"}]}]}]}, {"type": "PRIMARY", "title": "Terminal Phase Elimination Half-Life (t1/2) of Tezepelumab", "description": "Blood samples were collected to determine the t1/2 of tezepelumab and calculated as ln(2)/\u03bbZ, where \u03bbZ is the first-order rate constant associated with the terminal (log-linear) elimination phase. The PK parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "day", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.7", "spread": "5.94"}]}]}]}, {"type": "PRIMARY", "title": "Apparent Clearance (CL/F) of Tezepelumab", "description": "Blood samples were collected to determine the CL/F of tezepelumab and estimated as dose divided by AUC0-inf. The PK parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter per day", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0802", "spread": "0.0295"}]}]}]}, {"type": "PRIMARY", "title": "Apparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab", "description": "Blood samples were collected to determine the Vss/F of tezepelumab and estimated as CL/F\\*mean residence time (MRT), where MRT=Area under the moment curve of the analyte in the sampled matrix from zero (predose) extrapolated to infinite time/(AUC0-inf). The PK parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.08", "spread": "1.32"}]}]}]}, {"type": "PRIMARY", "title": "Apparent Volume of Distribution (Vz/F) of Tezepelumab", "description": "Blood samples were collected to determine the Vz/F of tezepelumab and estimated as CL/F\\*1/ \u03bbZ. The PK parameters were estimated using non-compartmental analysis method.", "populationDescription": "The PK analysis set included participants in the Safety Analysis set that had at least 1 detectable tezepelumab serum concentration from a sample collected postdose that was assumed not to be affected by factors such as important protocol deviations (eg, incorrect dose of study drug received).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.98", "spread": "1.26"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Anti-Drug Antibody (ADA) Response to Tezepelumab", "description": "Blood samples were analyzed for the presence of ADAs for tezepelumab using validated assays. ADA prevalence was defined as ADA positive at baseline and/or post baseline. ADA incidence was defined as the percentage of treatment-emergent ADA positive participants in a population. Treatment induced ADA positive was defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive was defined as baseline positive ADA titre that was boosted to a 4-fold or higher level following study drug administration. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive.", "populationDescription": "The Safety analysis set included all participants who received at least 1 dose of tezepelumab.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Predose and within \u00b1 1 hour of postdose on Day 1; on Days 29 and 85", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"title": "ADA prevalence", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Only baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Baseline and at least 1 post-baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Baseline ADA positive regardless of post-baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Any post-baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Treatment-induced ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Treatment-boosted ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Treatment-emergent ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "From the first dose administration (Day 1) up to study completion (End of Study/Day 85 visit) or withdrawal date", "description": "The Safety analysis set included all participants who received at least 1 dose of tezepelumab.", "eventGroups": [{"id": "EG000", "title": "Tezepelumab", "description": "Participants received a single dose of tezepelumab SC injection on Day 1.", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 7, "otherNumAtRisk": 18}], "otherEvents": [{"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2022-01-06", "uploadDate": "2023-03-29T09:51", "filename": "Prot_000.pdf", "size": 3155462}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-08-01", "uploadDate": "2023-03-29T09:51", "filename": "SAP_001.pdf", "size": 1317318}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}